Dr. Wei Shi is Senior Vice President of Clinical Development at Adagene. Dr. Shi has wide-ranging and in-depth experience in clinical development, medical affairs, translational medicine, and market research in oncology and rare genetic diseases.
Dr. Shi joined us from Amgen where she served as Oncology Clinical Development Head in China focused on early clinical development in solid tumors and hematologic malignancies. Prior to Amgen, she worked for international CRO, biotechnology, and pharmaceutical companies. As Senior Medical Director for Oncology Clinical Development at Covance, Dr. Shi was a key contributor to the medical strategy and execution of their clinical development program in solid tumors and hematologic malignancies. At BioMarin, she was Regional Medical Head JAPAC assessing treatments, including orphan drugs, for inherited metabolic and rare diseases. Later, as a senior member of their Global Oncology Development team, Dr. Shi led global early development programs in oncology. As the Medical Lead, Oncology, at Norvatis, she managed medical affairs and clinical development in the Hong Kong/Macau region.
Dr. Shi received her medical training from Tongji Medical University and Tongji Hospital in China and her Ph.D. in Life Science from Uppsala University in Sweden.